- Home
- ATYR vs MNOV Comparison
ATYR vs MNOV Comparison
Compare ATYR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | MNOV |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 76.5M |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ATYR | MNOV |
|---|---|---|
| Price | $0.78 | $1.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $8.75 | $7.00 |
| AVG Volume (30 Days) | ★ 2.6M | 102.9K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $190,000.00 | ★ $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $1.13 |
| 52 Week High | $7.29 | $2.24 |
Technical Indicators
Market Signals| Indicator | ATYR | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 56.81 |
| Support Level | $0.70 | $1.50 |
| Resistance Level | $0.83 | $1.60 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 57.87 | 68.42 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.